Viridian Therapeutics, Inc.
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Viridian Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 84 | 105 | +21 |
| Shares | 28.3M | 38.0M | +9.64M (+34.1%) |
| Value | $327.7M | $778.5M | +$450.8M (+137.6%) |
New holders (31)
Institutions that held Viridian Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (10)
Institutions that held Viridian Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 980,302 | $11.3M |
| Ally Bridge Group (NY) LLC | 496,012 | $5.74M |
| Franklin Resources Inc | 250,000 | $2.89M |
| Bridger Management, LLC | 66,300 | $767.0K |
| Alliancebernstein L.P. | 50,479 | $584.0K |
| Affinity Asset Advisors, LLC | 20,660 | $239.0K |
| Caption Management, LLC | 17,777 | $206.0K |
| Atom Investors LP | 10,699 | $124.0K |
| PDT Partners, LLC | 10,114 | $117.0K |
| Lindbrook Capital, LLC | 1,006 | $12.0K |